WOOJUNG BIO, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,637 KRW | +0.12% |
|
-1.15% | -21.67% |
| Sales 2022 | 46.92B 34.11M 46.59M | Sales 2023 | 38.62B 28.07M 38.35M | Capitalization | 27.08B 19.69M 26.89M |
|---|---|---|---|---|---|
| Net income 2022 | -1.88B -1.37M -1.87M | Net income 2023 | -5.05B -3.67M -5.02M | EV / Sales 2022 | 1.58 x |
| Net Debt 2022 | 35.69B 25.94M 35.44M | Net Debt 2023 | 46.57B 33.86M 46.24M | EV / Sales 2023 | 1.91 x |
| P/E ratio 2022 |
-20.5
x | P/E ratio 2023 |
-5.29
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 54.3% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.12% | ||
| 1 week | -1.15% | ||
| Current month | -11.99% | ||
| 1 month | -13.43% | ||
| 3 months | -13.66% | ||
| 6 months | -14.34% | ||
| Current year | -21.67% |
1 week
1 620.00
1 701.00
1 month
1 620.001 997.00
Current year
1 620.002 490.00
1 year
1 620.004 125.00
3 years
1 620.009 700.00
5 years
1 620.0014 800.00
10 years
1 620.0014 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 94-08-31 | |
Jin-Hyeon Jeong
IND | Independent Dir/Board Member | 65 | - |
Chan-Hyung Hong
BRD | Director/Board Member | 49 | 04-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jong-Wook Lee
CHM | Chairman | 75 | - |
| Chief Executive Officer | 66 | 94-08-31 | |
Jin-Woo Kim
BRD | Director/Board Member | 50 | 97-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1,637 | +0.12% | 22,615 |
| 24-04-25 | 1,635 | -2.04% | 37,592 |
| 24-04-24 | 1,669 | +1.15% | 24,704 |
| 24-04-23 | 1,650 | +0.67% | 34,046 |
| 24-04-22 | 1,639 | -1.03% | 68,867 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Woojung Bio Inc is a Korea-based company principally engaged in the biological business. The Company operates its business through two segments. The Infection Control Business segment is engaged in the manufacture and sale of reagents, breeding equipment, hydrogen peroxide sterilizers and other products. The Biological Business segment is engaged in the provision of test agency, research service and passage management services.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -21.67% | 16.22M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- A215380 Stock
